{"entity":{"id":"nct07439211","kind":"trial","name":"Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia","aka":[],"tldr":"A phase 1 trial of Eganelisib run by Jacqueline Garcia, MD, now recruiting.","summary":"Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia is a phase 1 interventional study registered as NCT07439211 by Jacqueline Garcia, MD, with 48 participants planned, started 2026-04-13. Conditions recorded: Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia and Refractory Leukemia. Interventions recorded: Eganelisib, Azacitidine and Venetoclax.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07439211","url":"https://clinicaltrials.gov/study/NCT07439211"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["eganelisib"],"companies":["stelexis-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07439211","phase":"1","setting":"Safety of Targeting PI3Kgamma Signaling With Azacitidine, Venetoclax and Eganelisib in Acute Myeloid Leukemia: A Phase 1 Study (GAVEL)","sponsor":"Jacqueline Garcia, MD","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07439211/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"eganelisib","kind":"drug","name":"Eganelisib","route":"/drugs/eganelisib/"}],"company":[{"id":"stelexis-biosciences","kind":"company","name":"Stelexis BioSciences","route":"/companies/stelexis-biosciences/"}]}}